Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea.
For about 25 million Americans who suffer from obstructive sleep apnea, there are various effective treatments such as CPAP breathing machines, surgery, a dental mouthpiece and even an implantable pac ...
The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.
The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...
Check out all our end-of-year content—the latest Heart Sounds podcast reviews the reporters’ own favorite stories for 2024, ...
The third ‘Downton Abbey’ film honors the late Dame Maggie Smith and her iconic portrayal of Violet Crawley. The drug is ...
Clinical research by Zepbound's manufacturer Eli Lilley found that the drug's active ingredient tirzepatide reduces sleep apnea by about 60%.
By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...
The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).
The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...
On Dec. 20, the FDA announced that the agency has approved Eli Lilly's Zepbound (tirzepatide) to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. The drug is to be ...
Opens in a new tab or window The FDA approved tirzepatide (Zepbound) for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity, the agency announced late Friday. Used along with ...